On June 24, 2026, Microsoft’s Digital Crimes Unit (DCU) facilitated the takedown, suspension, and blocking of domains that ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

As agent-based AI systems grow more sophisticated, developers are moving well beyond basic Retrieval-Augmented Generation (RAG) into a new era of autonomous, tool-integrated, and multi-agent ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Ready to develop your first AWS Lambda function in Python? It really couldn’t be easier. The AWS ...

Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be interested in buying on weakness, primarily because of its dealings with the ...